Agentless security for untouchable IoT devices

Tern plc

The rapid expansion of connected devices across enterprise and industrial environments presents a pressing security challenge for organisations preparing for 2026 and beyond. Increasingly, a large portion of a company’s device estate cannot be secured through traditional software agents or conventional update mechanisms. Many sensors, embedded controllers, medical instruments and legacy systems are either incapable of running additional software, cannot tolerate downtime for patching, or are geographically dispersed in remote or hostile environments.

Conventional endpoint security, built on the assumption that every device can host a monitoring agent, struggles at scale in environments where devices are resource constrained or run proprietary firmware. Attempting to retrofit traditional security tools often results in blind spots across thousands of device types from hundreds of vendors, increasing attack surface and operational complexity.

Agentless IoT security reframes this problem by decoupling protection from the devices themselves. Instead of installing security software on each endpoint, agentless solutions observe devices from the outside. They use network traffic analysis, infrastructure logs and application interfaces to discover and classify every IP‑connected device. By doing so, organisations gain visibility into assets they did not even know existed. This inventory of devices and behaviours becomes the foundation for identity‑based controls and policy enforcement that can be applied without touching the device itself.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines uses AI to turn medical congress discussions into pharma insights

Talking Medicines uses AI to analyse healthcare professional conversations at medical congresses, turning discussions into structured insights that help...

Novo Nordisk deal puts focus on next generation of oral GLP-1 treatments

Novo Nordisk secures rights to Hengrui's investigational HRS-1596 in a potential $2.6bn deal, targeting the development of once-weekly oral...

Device Authority warns supermarket freezer cyberattack exposes connected device security risks

Device Authority warns that a cyberattack affecting around 700 French supermarkets exposes security weaknesses in connected industrial equipment and...

Breast cancer research highlights importance of patient intelligence in pharma

Talking Medicines highlights how AI-powered patient intelligence can help pharmaceutical companies understand breast cancer treatment experiences and identify unmet...

GLP-1 drugs linked to emerging research into mental health and addiction

Research into GLP-1 medicines is expanding beyond weight loss, with studies examining potential links to depression, cognitive function, alcohol...

Talking Medicines examines emerging links between GLP-1 drugs and mental health

Researchers are investigating the potential links between GLP-1 medicines and mental health, with early findings prompting further studies into...

Search